# Adel Nada

> Adel Nada is a Boston-based company founder, executive and adviser. A co-founder and former president and CEO of GentiBio, he helped lead its two financing rounds and 2022 Bristol Myers Squibb collaboration. His current public roles include board chair at Akribion Therapeutics, venture partner at Volnay Therapeutics, and co-founder and executive chair at FytonBio.

- **Role:** Board Chair at Akribion Therapeutics; Venture Partner at Volnay Therapeutics; Co-founder and Executive Chair at FytonBio
- **Organizations:** Akribion Therapeutics, Volnay Therapeutics, FytonBio, Alia Therapeutics, GentiBio, Vycellix, Casebia Therapeutics, Intellia Therapeutics, Caladrius Biosciences, Baxter, Abbott, Rush University
- **Education:** Medical degree, Alexandria University, Master’s degree in Clinical Research, Rush University, Advanced studies in drug development, University of California, San Francisco, Advanced studies in drug development, University of Basel
- **Known for:** Helped lead GentiBio through $20 million seed and $157 million Series A financings., Led GentiBio when it announced its 2022 Bristol Myers Squibb collaboration., Appointed independent board director at Alia Therapeutics and board chair at Akribion Therapeutics.

## Career timeline

- **Before 2020** — Held an academic position at Rush and industry roles at Abbott, Baxter, Caladrius, Intellia and Casebia.
- **2019** — Named to Vycellix’s inaugural scientific advisory board.
- **2020** — Co-founded GentiBio; company announced $20 million seed financing on August 5.
- **2021** — Led GentiBio as president and CEO when it announced a $157 million Series A on August 11.
- **2022** — GentiBio announced its BMS collaboration on August 10 during his CEO tenure.
- **2023** — Alia Therapeutics announced his appointment as an independent board director in May.
- **2025** — Akribion publicly announced his board chair appointment in February; FytonBio identified him as co-founder and executive chair in August.

## Achievements

- Helped lead GentiBio through $20 million seed and $157 million Series A financings.
- Led GentiBio when it announced its 2022 Bristol Myers Squibb collaboration.
- Appointed independent board director at Alia Therapeutics and board chair at Akribion Therapeutics.
- Co-founded FytonBio, an inaugural Monash Ventures Pre-Seed Fund recipient.

## Latest updates

- **2025-08** — Breakthrough Victoria identified Nada as FytonBio’s co-founder and executive chair when describing its A$1 million pre-seed investment.
- **2025-02** — Akribion announced his appointment as board chair alongside its €8 million seed financing.

## Links

- LinkedIn: https://www.linkedin.com/in/adelnada70/

---

Profile page: https://yespress.io/adel-nada
Published by YesPress — https://yespress.io
Last updated: 2026-10-15